Safety Profile Considerations for Enfortumab Vedotin Plus Pembrolizumab

This approval of durvalumab marks the first and only perioperative immunotherapy regimen available in muscle-invasive bladder cancer.

Belzupacap sarotalocan showed rapid immune activation and a favorable safety profile as a treatment for non–muscle-invasive bladder cancer.

A propensity-score matched cohort study found a significantly reduced risk of recurrence of bladder cancer in patients who had blue light vs white light cystoscopy.

An expanded access program evaluating cretostimogene grenadenorepvec was highlighted during the 25th Annual Meeting of the Society of Urologic Oncology.

Jason M. Hafron, MD, CMO, discusses recent approvals in the non–muscle-invasive bladder cancer space and data from several clinical trials evaluating agents for bladder cancer.

Treatment of unresponsive non–muscle-invasive bladder cancer with nadofaragene firadenovec showed a 66% chance of survival and cystectomy-free status at 60 months.